Last updated: March 2, 2026
What Is NDC 82089-0102?
NDC 82089-0102 corresponds to Sodium Hyaluronate (0.2%) and Dextran (3%) ophthalmic solution. This product is used to treat dry eye syndrome by lubricating the ocular surface, improving symptoms such as irritation and discomfort.
Market Overview
Market Size and Demand Drivers
The global dry eye treatment market was valued at approximately $4 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030.[1] The rise in age-related ocular conditions, increasing screen time, and heightened awareness of dry eye management contribute to this growth.
Competitive Landscape
Major competitors include:
- Restasis (cyclosporine 0.05%) by AbbVie
- Xiidra (lifitegrast 5%) by Novartis
- Generics of artificial tears and other ocular lubricants
The entry of products like NDC 82089-0102 hinges on reimbursement policies, clinical trial outcomes, and formulary acceptance.
Regulatory Status
- Approved by the FDA; labeled for OTC or prescription use depending on formulation and indications.
- Market adoption depends on approval status in key markets, including the U.S., EU, and emerging economies.
Price Analysis
Historical Pricing Data
- Brand Name equivalents (Restasis, Xiidra): retail prices range from $400 to $600 per bottle (30 mL), with actual patient costs often reduced via insurance.[2]
- Generics and OTC solutions: typically priced between $20 and $50 per bottle, reflecting lower manufacturing costs.
Cost Factors
- Ingredient complexity
- Regulatory compliance
- Manufacturing scale
- Distribution channels
Projected Pricing for NDC 82089-0102
| Year |
Estimated Retail Price (per 15 mL bottle) |
Factors Influencing Price |
| 2023 |
$50 – $70 |
Entry of a new product, moderate competition |
| 2025 |
$45 – $65 |
Increased manufacturing efficiency, competition stabilization |
| 2030 |
$40 – $60 |
Market saturation, potential biosimilar entry |
Pricing is expected to decrease over five years due to competitive pressure and market maturation, aligning with trends observed in similar ophthalmic solutions.
Market Entry and Revenue Potential
Licensing and Reimbursement
- Securing insurance reimbursement will influence market penetration.
- Brand recognition influences prescribing patterns, especially if the product demonstrates improved efficacy or tolerability.
Revenue Estimates
- Initial annual sales forecast: $100 million domestically within three years of launch, assuming a market share of 2–3% of dry eye segment.
- Long-term revenue potential could reach $250 million annually with expansion into international markets and expanded indications.
Risks and Challenges
- Regulatory delays could postpone market entry.
- Competition from established brands with strong market presence.
- Price erosion due to generic conversions and biosimilar entries.
Key Takeaways
- NDC 82089-0102 targets a large, growing dry eye segment with projected revenue potential of $100-250 million annually in key markets.
- Pricing is expected to start at $50–$70 per 15 mL bottle, declining over time due to market competition.
- Commercial success hinges on regulatory approval, reimbursement, and differentiation from existing therapies.
FAQs
Q1: What are the main competitors for NDC 82089-0102?
Restasis, Xiidra, and various artificial tears brands compete in the dry eye treatment space.
Q2: How does the pricing of NDC 82089-0102 compare to existing products?
It is projected to be similar to branded products initially, around $50–$70 per bottle, with subsequent declines similar to generics.
Q3: What factors could influence the market share of this drug?
Reimbursement policies, efficacy clinical data, physician acceptance, and formulary placements.
Q4: Will insurance coverage impact the drug’s market success?
Yes, insurance reimbursement can significantly influence prescribing patterns and patient affordability.
Q5: How might international markets differ in pricing and adoption?
Pricing may be lower due to regional competition and regulatory differences; adoption depends on local healthcare policies.
Sources
[1] MarketsandMarkets. (2022). Dry Eye Disease Market by Treatment, End User, and Region.
[2] GoodRx. (2023). Cost of prescription eye medications.
